Secarna Pharmaceuticals GmbH & Co. KG, a biotechnology company focused on next-generation oligonucleotide therapeutics, has announced a strategic collaboration with Scenic Biotech B.V., known for its work in modifier therapies for severe genetic disorders.
The agreement involves the joint discovery and co-development of oligonucleotide therapies targeting a novel disease mechanism identified and validated using Scenic’s proprietary Cell-Seq platform.
Under the partnership, Secarna will lead oligonucleotide discovery efforts using its AI-powered OligoCreator platform, which accelerates the drug discovery process from target selection to therapeutic candidate development. OligoCreator’s technology enables rapid identification and characterization of potentially safe and effective oligonucleotide candidates.
Meanwhile, Scenic Biotech will contribute its deep expertise in target and disease biology, leveraging its Cell-Seq technology to uncover genetic modifiers that can transform disease outcomes.
“We are really excited to collaborate with Scenic to develop first-in-class disease-modifying oligonucleotide therapies for severe genetic diseases,” said Konstantin Petropoulos, PhD, CEO of Secarna Pharmaceuticals. “Our complementary technologies—Scenic’s Cell-Seq and Secarna’s OligoCreator—create a powerful framework for discovering breakthrough treatments for patients with currently untreatable conditions.”
This collaboration reflects both companies’ shared commitment to advancing precision medicine and creating transformative therapies for patients with unmet medical needs.
About Secarna Pharmaceuticals
Secarna Pharmaceuticals is a biopharmaceutical company redefining the discovery and development of best-in-class oligonucleotide therapeutics. Its mission is to deliver disease-modifying therapies that address conditions beyond the reach of existing treatment modalities.
